头颈鳞癌放疗联合免疫检查点抑制剂不增加甲状腺功能减退风险
本研究为单中心回顾性队列研究,比较头颈鳞癌患者单纯放疗(±化疗和手术)(n=101)与联合抗PD-1/PD-L1治疗(n=38)后甲状腺功能减退的发生率。结果显示两组临床或亚临床甲状腺功能减退发生率无显著差异,多因素分析年龄、性别、BMI亦无显著影响。结论认为在标准治疗基础上加用抗PD-1/PD-L1治疗不显著增加甲状腺功能减退风险,证据等级为3。
要点
- 头颈鳞癌放疗联合抗PD-1/PD-L1治疗未显著增加甲状腺功能减退风险
- 两组临床或亚临床甲状腺功能减退发生率无显著差异
- 年龄、性别、BMI与甲状腺功能减退无显著关联
核心结论
- 在头颈鳞癌标准治疗中加入抗PD-1/PD-L1治疗不显著增加甲状腺功能减退的发生风险。
研究设计与样本
- 回顾性单中心队列研究,放疗组n=101,放疗联合抗PD-1/PD-L1组n=38。
主要发现
- 两组临床或亚临床甲状腺功能减退发生率无显著差异。
- 多项逻辑回归显示年龄、性别、BMI与甲状腺功能减退无显著差异。
临床怎么用
- 头颈鳞癌患者接受放疗联合抗PD-1/PD-L1治疗时,甲状腺功能减退风险与单纯放疗相比未见显著增加。
局限性
- 研究为回顾性单中心设计,证据等级为3。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Hypothyroidism is a relatively common complication of head and neck squamous cell carcinoma (HNSCC) treatment. The objective of this study was to determine whether the addition of programmed death ligand-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibition (anti-PD-1/PD-L1 therapy) to standard treatment increases the risk of hypothyroidism in HNSCC. STUDY DESIGN: Retrospective Cohort. METHODS: This is a retrospective, single institutional cohort study. Patients who received radiotherapy (RT) for HNSCC were identified in the electronic medical record. Patient factors collected include age, sex, body mass index (BMI), smoking status, alcohol use, Charlson comorbidity index, and HNSCC treatment records. The rate of hypothyroidism for patients with HNSCC receiving RT (+/- chemotherapy and surgery) (RT group, n = 101) was compared to that of HNSCC patients receiving RT (+/- chemotherapy and surgery) + anti-PD-1/PD-L1 therapy, either concurrently or after RT (RT + anti-PD-1/PD-L1 group, n = 38). RESULTS: There was no significant difference in the rate of clinical or subclinical hypothyroidism between the two groups. Multinomial logistic regression found no significant difference in hypothyroidism based on age, sex, or BMI. CONCLUSIONS: The addition of anti-PD-1/PD-L1 therapy to standard HNSCC treatment does not significantly increase the risk of developing hypothyroidism. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E2413-E2419, 2021.
引用
- Leddon JL, Chirra M, Frankart AJ, et al. Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors. Laryngoscope. 2021. PMID: 33609046. doi:10.1002/lary.29451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。